dc.contributor.author | Sando, Karen R. | eng |
dc.contributor.author | Taylor, James | eng |
dc.contributor.other | Family Physicians Inquiries Network | eng |
dc.date.issued | 2011 | eng |
dc.description.abstract | For obese patients with type 2 diabetes (T2D) who do not tolerate other diabetes medications or for patients who need only a minimal reduction in glycosylated hemoglobin (A1c) to reach goal, bromocriptine may be a therapeutic agent to consider. | eng |
dc.identifier.uri | http://hdl.handle.net/10355/12126 | |
dc.language | English | eng |
dc.publisher | Family Physicians Inquiries Network | eng |
dc.relation.ispartofcollection | Priority Updates to Research Literature (PURLs) (2011) | eng |
dc.relation.ispartofcommunity | University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network | eng |
dc.relation.ispartofseries | Journal of family practice, 60, no. 11 (November 2011): E1-E5. | eng |
dc.rights | OpenAccess. | eng |
dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | eng |
dc.subject.lcsh | Non-insulin-dependent diabetes | eng |
dc.subject.lcsh | Diabetes -- Treatment | eng |
dc.subject.lcsh | Bromocriptine | eng |
dc.subject.other | Type 2 diabetes | eng |
dc.subject.other | Obesity | eng |
dc.title | Bromocriptine: Its place in type 2 diabetes Tx | eng |
dc.type | Article | eng |